Severe, persistent pain in the upper abdomen — often boring through to the back — with nausea and vomiting that will not stop. That is the pancreatitis pattern.
Stop and seek medical assessment. Persistent vomiting also dehydrates and strains the kidneys — sip fluids.
Unrelenting abdominal pain, repeated vomiting, or signs of dehydration → urgent care or ER. And tell any anaesthetist before surgery: these drugs slow stomach emptying and raise the risk of aspiration under anaesthesia.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
Adds glucagon receptor agonism to the dual-incretin approach. The glucagon arm is hypothesised to raise energy expenditure and drive hepatic fat mobilisation, complementing the appetite suppression of GLP-1 and the adipose effects of GIP. The therapeutic challenge is balancing glucagon's energy-expenditure benefit against its hyperglycaemic potential — the incretin arms are intended to offset it.
Phase 2 results reported weight reductions larger than those seen with approved incretin agents, generating substantial attention. Phase 3 programmes are ongoing. Efficacy and safety are not established; no regulatory body has reviewed a complete dossier.
Not approved anywhere. Investigational. Material sold online as “research retatrutide” is not the clinical trial product, has no verified identity or purity chain, and is not lawfully available for human use.
Human safety profile is incompletely characterised by definition — that is what Phase 3 exists to determine. Trial data report dose-dependent gastrointestinal effects and heart-rate increases. Unknowns are the point: this is an unapproved investigational molecule.
Investigational — no approved dose. Phase 2 obesity trials titrated to weekly SC doses up to 12 mg under close monitoring. These are research doses, not an established regimen.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.